Related Experiment Video

Updated: Aug 6, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Apolipoprotein E Genotype and Coronary Heart Disease in a Mongolian Cohort: An Exploratory Case-Control Study

Ochgerel Dogsom1, Ariunzul Punsaldulam2, Odonchimeg Dogsom3

  • 1Department of Psychopathology Clinic, National Center Mental Health of Mongolia, Ulaanbaatar, Mongolia.

Anatolian Journal of Cardiology
|August 5, 2026
PubMed

Insights

The apolipoprotein E (APOE) genotype is linked to coronary heart disease (CHD) risk in Mongolians. Specific APOE genotypes, like ε2/ε3, may reduce CHD odds, independent of cholesterol levels.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Population Health

Background:

  • Investigating the link between apolipoprotein E (APOE) gene variations and coronary heart disease (CHD) risk.
  • Focusing on a specific Mongolian clinical cohort.

Purpose of the Study:

  • To determine the association between APOE gene polymorphisms and CHD risk in a Mongolian population.
  • To explore the role of genetic factors in cardiovascular disease risk assessment.

Main Methods:

  • A hospital-based case-control study involving 63 CHD patients and 61 healthy controls.
  • Assessment of anthropometric measurements, lipid profiles, and APOE genotypes.
  • Multivariable logistic regression analysis to identify risk factors.

Main Results:

  • Significant differences in APOE genotype distribution between CHD cases and controls (P = .009).
  • The APOE ε2/ε3 genotype was associated with significantly lower odds of CHD (OR = 0.29, P = .007).
  • Higher high-density lipoprotein cholesterol and lower total cholesterol observed in the CHD group.

Conclusions:

  • A significant association exists between APOE genotype and CHD in the Mongolian population.
  • APOE polymorphisms may influence CHD risk independently of absolute cholesterol levels.
  • Emphasizes the need for population-specific cardiovascular risk assessment considering genetic factors.
Abstract

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...